Vermillion, Inc. (NASDAQ:VRML) CEO, Valerie Palmieri, to Present at Women in Bio

Bio-analytical solutions company, Vermillion, Inc. (NASDAQ:VRML), announces that CEO Valerie Palmieri will present at the Women in Bio – NY Chapter meeting on October 20th.

AUSTIN, Texas, Oct. 19, 2016 /PRNewswire/ — Vermillion, Inc. (VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that CEO, Valerie Palmieri, will present at the Women in Bio – New York Chapter meeting at the PRIDE Global Event Space in New York, NY on October 20, 2016 at 6:00PM EST.  The presentation, titled “Ovarian Cancer: Changing the Early Detection Paradigm and Controlling Your Destiny” will describe the who, what, why and how of the country’s most deadly gynecologic malignancy.  The discussion will include a review of the disease symptoms, and how women can “listen” to their bodies and understand how modern diagnostics help identify cancer early, when it is still highly treatable. Ms. Palmieri will be joined by Sherry Pollex, life partner of NASCAR Sprint Cup driver Martin Truex, Jr and an ovarian cancer thriver.  Sherry will review her journey and will highlight how awareness can “truly” make a difference! 

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases.  The company’s initial in vitro diagnostic test, OVA1®, was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016 Vermillion received FDA clearance for Overa™, a second generation OVA1 test with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com.

Investor Relations Contact:

Michael Wood

LifeSci Advisors LLC

Tel 1-646-597-6983

mwood@lifesciadvisors.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vermillion-ceo-to-present-at-women-in-bio—new-york-300347524.html

Original Source

vermillion-graph

Vermillion, Inc. (NASDAQ:VRML) shares are moving -8.71% on the news today and have traded in the range of $1.04 – 1.16 during the current trading session. A number of brokerage analysts have recently weighed in on the stock, providing price target projections. The covering firms currently have a consensus one-year price target of $2.00 on the stock.  This is according to brokerage analysts polled by Thomson Reuters First Call.  This is the average number from the individual targets provided by the firms.  Analysts are projecting earnings per share of $-0.06 for the next fiscal quarter.  For the current year, analysts are predicting earnings of $-0.29 per share according to First Call.

Are Shares of Vermillion, Inc. (NASDAQ:VRML) Ready to Explode?  Sign up to our Newsletter to be the First to Know

Sign up to get our Free Penny Stock Picks Before the Street!

In looking at where Vermillion, Inc. (NASDAQ:VRML) is trading on a technical level, the stock is trading -19.13% away from its 50-day moving average of $1.29.  Based on the most recent available data, the equity is -52.73% off of its 52-week high of $2.20 and +13.04% away from its 52-week low which is $0.92.

Today, the stock opened at $1.11 and the last bid at the time of writing stood at $1.04.  During the session thus far, the equity dipped down to $1.04 and touched $1.16 as the high point.  Vermillion, Inc. (NASDAQ:VRML) has a market cap of $54.31M and has seen an average daily volume of 38,909 over the past three months.

Sign Up to Receive Breaking Alerts on Stocks That Are Primed to Make a Run in the Bar Below.

Sign up to get our Free Penny Stock Picks Before the Street!

Disclaimer: The views, opinions, and information expressed in this article are those of the authors and do not necessarily reflect the official policy or position of any company stakeholders, financial professionals, or analysts. Examples of analysis performed within this article are only examples. They should not be utilized to make stock portfolio or financial decisions as they are based only on limited and open source information. Assumptions made within the analysis are not reflective of the position of any analysts or financial professionals.

Related posts

Leave a Comment